Cadrenal Therapeutics, Inc.
CVKD
$15.50
-$0.775-4.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 90.27% | 28.81% | 7.95% | 11.46% | 50.11% |
| Depreciation & Amortization | -5.00% | -8.70% | 4.55% | 50.00% | 42.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.60% | 3.32% | -11.86% | -25.64% | 174.89% |
| Operating Income | -43.60% | -3.32% | 11.86% | 25.64% | -174.89% |
| Income Before Tax | -27.45% | 40.71% | 51.36% | 60.66% | -16.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.45% | 40.71% | 51.36% | 60.66% | -16.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.45% | 40.71% | 51.36% | 60.66% | -16.92% |
| EBIT | -43.60% | -3.32% | 11.86% | 25.64% | -174.89% |
| EBITDA | -43.61% | -3.32% | 11.87% | 20.14% | -232.74% |
| EPS Basic | 19.22% | 64.29% | 71.53% | 75.81% | 19.58% |
| Normalized Basic EPS | 10.49% | 62.32% | 70.03% | 74.52% | 27.42% |
| EPS Diluted | 19.22% | 64.29% | 71.53% | 75.81% | 19.58% |
| Normalized Diluted EPS | 10.49% | 62.32% | 70.03% | 74.52% | 27.42% |
| Average Basic Shares Outstanding | 35.66% | 40.12% | 63.73% | 70.25% | 124.89% |
| Average Diluted Shares Outstanding | 35.66% | 40.12% | 63.73% | 70.25% | 124.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |